Skip to main content

Table 1 Characteristics of cohorts, women with breast cancer stage I–III and IV, diagnosed 2006–2012

From: No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study

 

Stage I–III

Stage IV

(n = 21,414)

(n = 621)

Age at diagnosis

 < 40 years

883 (4.1)

17 (2.8)

 40–49 years

3114 (14.5)

63 (10.1)

 50–59 years

4597 (21.5)

109 (17.6)

 60–69 years

6546 (30.6)

132 (21.3)

 70–79 years

3679 (17.2)

154 (24.8)

 ≥ 90 years

2595 (12.1)

146 (23.6)

Age (years), median (range)

63 (19–102)

68 (29–97)

Region

 Stockholm-Gotland

9068 (42.4)

235 (37.8)

 Uppsala-Örebro

8868 (41.4)

263 (42.4)

 North

3478 (16.2)

123 (19.8)

Education

 < 10 years

5367 (25.1)

227 (36.6)

 10–12 years

8682 (40.5)

230 (37.0)

 > 12 years

7119 (33.2)

147 (23.7)

 Missing

246 (1.2)

17 (2.7)

Stage

 I

12,546 (58.6)

na

 II

7879 (36.8)

na

 III

989 (4.6)

na

 IV

na

621

HER2 status

 Positive

2407 (11.2)

50 (8.1)

 Negative

15,848 (74.0)

147 (23.7)

 Missing

3159 (14.8)

424 (68.3)

ER status

 Positive

17,514 (81.8)

166 (26.7)

 Negative

2907 (13.6)

60 (9.7)

 Missing

993 (4.6)

395 (63.6)

Breast cancer subtype

 Luminal (ER+, HER2–/HER2+)

15,529 (72.5)

141 (22.7)

 Nonluminal HER2 (ER–, HER2+)

857 (4.0)

34 (5.5)

 ER–HER2–

1739 (8.1)

18 (2.9)

 Missing

3289 (15.4)

428 (68.9)

Neoadjuvanta/adjuvant breast cancer treatment

 Chemotherapy

8401 (39.2)

97 (15.6)

 Endocrine therapy

16,160 (75.5)

141 (22.7)

 Radiotherapy

15,036 (70.2)

82 (13.2)

 Trastuzumab

1858 (8.7)

21 (3.4)

Aspirin

 Before breast cancer diagnosis (from 9 to 3 months)

2660 (12.4)

100 (16.1)

 After breast cancer diagnosis (3–9 months)

2813 (13.1)

na

 During entire follow up

4091 (19.1)

na

Aspirin treatment, duration (total, at end of follow-up)

 < 6 months

485 (2.3)

na

 6 months–2 years

1552 (7.2)

na

 > 2 years

2054 (9.6)

na

Dose of aspirin (total, at end of follow-up)

 < 75 mg/day

24 (0.1)

na

 75 mg/day

3486 (16.3)

na

 > 75 to < 160 mg/day

258 (1.2)

na

 160 mg/day

223 (1.0)

na

 > 160 mg/day

100 (0.5)

na

  1. Data presented as n (%) unless indicated otherwise. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, na not applicable
  2. aNeoadjuvant radiotherapy, 41 women (0.2%); neoadjuvant chemotherapy, 891 women (4.1%); neoadjuvant endocrine therapy, 691 women (3.2%)